A self-powered bidirectional partition microfluidic chip with embedded microwells for highly sensitive detection of EGFR mutations in plasma of non-small cell lung cancer patients

被引:18
|
作者
Wu, Wenshuai [1 ,2 ]
Wu, Fengtian [3 ]
Zhang, Shan [1 ,2 ]
Ding, Xiong [1 ,2 ]
Zhang, Tao [1 ]
Yang, Ying [3 ]
Mu, Ying [1 ]
机构
[1] Zhejiang Univ, Res Ctr Analyt Instrumentat, Inst Cyber Syst & Control, State Key Lab Ind Control Technol, Hangzhou 310027, Peoples R China
[2] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Coll Med,Collaborat Innovat Ctr Diag & Treatment, Natl Clin Res Ctr Infect Dis,State Key Lab Diag &, Hangzhou 310058, Peoples R China
基金
国家重点研发计划;
关键词
Digital PCR chip; Bidirectional partition network; Embedded microwell; Self-powered; CtDNA analysis; Tumor dynamics monitoring; GROWTH-FACTOR RECEPTOR; CIRCULATING TUMOR DNA; DROPLET DIGITAL PCR; KRAS MUTATIONS; ABSOLUTE QUANTIFICATION; PDMS; PLATFORM;
D O I
10.1016/j.talanta.2020.121426
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Circulating tumor DNA (ctDNA) is a promising biomarker for tumor genotyping and therapy monitoring. Herein, we developed a digital PCR chip with embedded microwell and bidirectional partition network for highly sensitive ctDNA analysis. The embedded microwell contributes to increasing microreaction density (up to 7000 microwells/cm(2)) and reducing evaporation during amplification. The bidirectional partition network can achieve fast and random distribution of targets, ensuring the precise quantification of nucleic acid. We used plasmids, artificial samples and 32 clinical blood samples from non-small cell lung cancer patients to test the performance of this platform. The results demonstrated that our chip has not only comparable quantification performance to commercial counterpart but also the ability to detect EGFR mutations with as low as 0.01% mutation rate and 20 alter molecules in 27 ng genomic DNA. The identification of EGFR mutations in plasma using developed chip exhibited 85.71% sensitivity and 94.44% specificity for L858R mutation and 100% sensitivity and 86.96% specificity for T790 M mutation. Moreover, the monitoring of mutant allele in plasma was accomplished in this work. In conclusion, the developed chip has a potential in lung tumor genotyping and therapy monitoring for precision medicine, even other tumors.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND CORRELATION WITH SENSITIVITY TO ERLOTINIB
    Ricciardi, S.
    Tedesco, B.
    Migliorino, M. R.
    Graziano, P.
    Leone, A.
    Di Salvia, M.
    Capodaglio, V.
    Condo, S.
    De Santis, S.
    De Marinis, F.
    EJC SUPPLEMENTS, 2008, 6 (14): : 134 - 134
  • [42] The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer
    Karachaliou, Niki
    Angel Molina-Vila, Miguel
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) : 241 - 244
  • [43] The Impact of EGFR Mutations. Treatment with ITKs in Non-Small Cell Lung Cancer Patients
    Garcia Manrique, T.
    Saavedra, O.
    Palazon Carrion, N.
    Perez Gago, C.
    Calvete, J.
    Carrillo, R.
    Valdivia Garcia, F. J.
    Vicente Baz, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2146 - S2146
  • [44] Prevalence of EGFR mutations in non-small cell lung cancer (NSCLC) smoker patients.
    Izarzugaza, Yann
    Domine, Manuel
    Rojo, Federico
    Casado, Victoria
    Leon, Ana
    Jesus Fernandez-Acenero, Maria
    Rubio, Gustavo
    Cordova, Sharon
    Madoz, Juan
    Ignacio Martin-Valades, Jose
    Luis Arranz, Juan
    Serrano, Gloria
    Carames, Cristina
    Zazo, Sandra
    Rincon, Raul
    Canadas, Carmen
    Perez-Gonzalez, Nuria
    Campos, Angel
    Lobo, Francisco
    Garcia-Foncillas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients
    Scodes, Simona
    Cappuzzo, Federico
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2020, 14 (06) : 565 - 576
  • [46] The efficacy of erlotinib for patients with non-small cell lung cancer with wild type of EGFR mutations
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Tanabe, Tsuyoshi
    Tsushima, Kenji
    Urushihata, Kazuhisa
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    Kubo, Keishi
    Koyama, Shigeru
    Ooura, Nariaki
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S690 - S690
  • [47] Prevalence of EGFR mutations in patients with Non-Small Cell Lung Cancer (NSCLC) in Turkish population
    Sener, E.
    Kosemehmetoglu, K.
    Tezel, G. Guler
    VIRCHOWS ARCHIV, 2013, 463 (02) : 320 - 320
  • [48] The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients
    Li, Min
    Zhou, Cheng-Zhi
    Yang, Jin-Ji
    Lu, Shun
    Zheng, Di
    Hu, Jie
    Zeng, Hui
    Lu, You
    Lu, Kai-Hua
    Li, Shu-Ang
    Mao, Xin-Ru
    Han-Zhang, Han
    Lizaso, Analyn
    Ye, Jun-Yi
    Hu, Cheng-Ping
    CANCER BIOLOGY & THERAPY, 2019, 20 (08) : 1097 - 1104
  • [49] EGFR mutations and tumor metastases in patients with non-small cell lung cancer in the South of Russia
    Kit, Oleg I.
    Vodolazhsky, Dmitry I.
    Timoshkina, Natalia N.
    Vladimirova, Lubov' Yu
    Turkin, Igor N.
    Kutsyn, Ksenia A.
    Enin, Yaroslav S.
    Panina, Svetlana B.
    Jurisic, Vladimir
    JOURNAL OF BUON, 2017, 22 (06): : 1410 - 1415
  • [50] ANALYSIS OF THE EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER PATIENTS AFTER EGFR-TKIS TREATMENT
    Matsuo, Midori
    Nanae, Tomonaga
    Koichi, Izumikawa
    Hiroyuki, Yamaguchi
    Takaya, Ikeda
    Katsumi, Nakatomi
    Yoichi, Nakamura
    Kazuhiro, Tsukamoto
    Shigeru, Kohno
    RESPIROLOGY, 2010, 15 : 68 - 68